Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
Rubraca™ (rucaparib) approved and launched in the U.S. on December
19, 2016 for the treatment of advanced BRCA-mutant ovarian cancer
$266.2M in cash, cash equivalents and available for sale securities
at December 31, 2016
$487.4M in adjusted cash, cash equivalents and available for sale
securities at December 31, 2016 as adjusted for the January 2017
financing proceeds of $221.2 million
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 9, 2017--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth
quarter/year-end 2016 financial results on Wednesday, February 22, 2017,
after the close of the U.S. financial markets. Clovis’ senior management
will host a conference call and live audio webcast at 4:30 p.m. ET that
day to discuss the company’s results in greater detail.
The conference call is being webcast and can be accessed from the ...
Strata Trial to Identify Genetically Selected Patients Eligible
for Enrollment in Clovis’ TRITON Studies in Advanced Prostate Cancer
BOULDER, Colo. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 1, 2017--
Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today
announced an agreement to accelerate patient identification and
enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate
Indications) clinical trial program, which includes...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.